Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 565-575 , July 2010

Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET

  • Romain Bejot

      Affiliations

    • Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford OX1 3TA, United Kingdom
    • Current address: Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A⁎STAR), #02-02 Helios, 11 Biopolis Way, Singapore 138667. Tel.: +6564788737.
    • ,
  • Veerle Kersemans

      Affiliations

    • Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford OX1 3TA, United Kingdom
    • ,
  • Catherine Kelly

      Affiliations

    • Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford OX1 3TA, United Kingdom
    • ,
  • Laurence Carroll

      Affiliations

    • Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford OX1 3TA, United Kingdom
    • ,
  • Robert C. King

      Affiliations

    • Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford OX1 3TA, United Kingdom
    • ,
  • Véronique Gouverneur

      Affiliations

    • Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford OX1 3TA, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 1865275644.

Received 24 February 2010 ,Revised 18 March 2010 ,Accepted 21 March 2010.

References 

  1. Brown JM. The hypoxic cell: a target for selective cancer therapy — eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1999;59:5863–5870
  2. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(suppl):129S–148S
  3. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408–1416
  4. Chan D, Giaccia A. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 2007;26:333–339
  5. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705–713
  6. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8:425–437
  7. Svastová E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004;577:439–445
  8. Gatenby RA, Smallbone K, Maini PK, et al. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer. 2007;97:646–653
  9. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988;14:831–838
  10. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer. 1981;43:546–550
  11. Grunbaum Z, Freauff SJ, Krohn KA. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med. 1987;28:68–75
  12. Lee ST, Scott AM. Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole. Semin Nucl Med. 2007;37:451–461
  13. Brown JM, Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res. 1980;82:171–190
  14. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging. 2008;1–10
  15. Barthel H, Wilson H, Collingridge DR, et al. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer. 2004;90:2232–2242
  16. Yamamoto F, Oka H, Antoku S, Ichiya YI, Masuda K, Maeda M. Synthesis and characterization of lipophilic 1-[18F]fluoroalkyl-2-nitroimidazoles for imaging hypoxia. Biol Pharm Bull. 1999;22:590–597
  17. Zanzonico P, O'Donoghue J, Chapman J, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging. 2004;31:117–128
  18. Kumar P, Ohkura K, Beiki D, Wiebe LI, Seki KI. Synthesis of 1-β-d-(5-deoxy-5-iodoarabinofuranosyl)-2-nitroimidazole (β-IAZA): A novel marker of tissue hypoxia. Chem Pharm Bull. 2003;51:399–403
  19. Chu T, Li R, Hu S, Liu X, Wang X. Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)-propanhydroxyiminoamide (N2IPA) as a tumor hypoxia marker. Nucl Med Biol. 2004;31:199–203
  20. Procissi D, Claus F, Burgman P, et al. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res. 2007;13:3738–3747
  21. Sugie C, Shibamoto Y, Ito M, et al. Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo. J Radiat Res. 2005;46:453–459
  22. Dobrowsky W, Huigol NG, Jayatilake RS, et al. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial. Radiother Oncol. 2007;82:24–29
  23. Nagao Y, Sano S, Ochiai M, et al. Radiosensitizing hypoxic cells with new 3-nitro-1,2,4-triazole derivatives in vitro and in vivo. Chem Pharm Bull. 1989;37:1951–1953
  24. Shibamoto Y, Nishimoto SI, Shimokawa K, et al. Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers. Int J Radiat Oncol Biol Phys. 1989;16:1045–1048
  25. Liu Y, Xu Y, Qian X, et al. Novel fluorescent markers for hypoxic cells of naphthalimides with two heterocyclic side chains for bioreductive binding. Bioorg Med Chem. 2006;14:2935–2941
  26. Elizarov AM. Microreactors for radiopharmaceutical synthesis. Lab Chip. 2009;9:1326–1333
  27. Lim JL, Berridge MS. An efficient radiosynthesis of [18F]fluoromisonidazole. Appl Radiat Isot. 1993;44:1085–1091
  28. Prekeges JL, Rasey JS, Grunbaum Z, Krohn KH. Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol. 1991;42:2387–2395
  29. Varghese AJ. Glutathione conjugates of misonidazole. Biochem Biophys Res Commun. 1983;112:1013–1020
  30. Hewitt HB, Blake E, Porter EH. Effect of lethally irradiated cells on transplantability of murine tumors. Br J Cancer. 1973;28:123–135
  31. Akaike HA. New look at the statistical model identification. Automatic control. IEEE Transactions on. 1974;19:716–723
  32. Hwang DR, Dence CS, Bonasera TA, Welch MJ. No-carrier-added synthesis of 3-[18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol. A potential PET agent for detecting hypoxic but viable tissues. Appl Radiat Isot. 1989;40:117–126
  33. Tewson TJ. Synthesis of [18F]fluoroetanidazole: a potential new tracer for imaging hypoxia. Nucl Med Biol. 1997;24:755–760
  34. Briard E, Pike VW. Substitution-reduction: an alternative process for the [18F]N-(2-fluoroethylation) of anilines. J Labelled Compd Radiopharm. 2004;47:217–232
  35. Osborn NJ, Grigg J, Pettitt RP, Wilson A, Anthony PN, Osborn NJ, et al. Fluoridation process for the synthesis of 2-[18F]fluoro-2-deoxy-d-glucose. US patent EP1817320. 2006;
  36. Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer. 2005;5:152
  37. [18F]Fluoromisonidazole. [18F]FMISO. In: Molecular imaging and contrast agent database (MICAD) [database online]. Bethesda (MD): National Library of Medicine (US), NCBI; 2004-2008;Available from: http://micad.nih.gov
  38. Kagiya T, Nishimoto SI, Shibamoto Y, et al. Importance of tumor affinity of nitroazoles in hypoxic radiosensitization. Int J Radiat Oncol Biol Phys. 1989;16:1033–1037
  39. Clarke ED, Goulding KH, Wardman P. Nitroimidazoles as anaerobic electron acceptors for xanthine oxidase. Biochem Pharmacol. 1982;31:3237–3242
  40. Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res. 1983;43:1523–1528
  41. Koch CJ, Stobbe CC, Baer KA. Metabolism induced binding of 14C-misonidazole to hypoxic cells: Kinetic dependence on oxygen concentration and misonidazole concentration. Int J Radiat Oncol Biol Phys. 1984;10:1327–1331
  42. Casciari JJ, Graham MM, Rasey JS. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med Phys. 1995;22:1127–1139
  43. Raleigh JA, Franko AJ, Koch CJ, Born JL. Binding of misonidazole to hypoxic cells in monolayer and spheroid culture: evidence that a side-chain label is bound as efficiently as a ring label. Br J Cancer. 1985;51:229–235
  44. Raleigh JA, Liu SF. Reductive fragmentation of 2-nitroimidazoles: amines and aldehydes. Int J Radiat Oncol Biol Phys. 1984;10:1337–1340

PII: S0969-8051(10)00068-5

doi: 10.1016/j.nucmedbio.2010.03.011

Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 565-575 , July 2010

Article Tools

* Image Usage & Resolution